Beranda › Melanoma Uveal › Pennsylvania
Uji klinis Melanoma Uveal di Pennsylvania
8 studi untuk Melanoma Uveal mencari peserta di lokasi di Pennsylvania.
Kota di Pennsylvania
Teks studi resmi (Bahasa Inggris)
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
- Wills Eye Hospital at Thomas Jefferson University, Philadelphia
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT07804186Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
- UPMC Hillman Cancer Center, Pittsburgh
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06070012Tebentafusp-tebn With LDT in Metastatic UM
- Thomas Jefferson University, Philadelphia
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Jul 2026 · NCT06626516Neoadjuvant Tebentafusp for Uveal Melanoma
- Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Jun 2026 · NCT06414590Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Jun 2026 · NCT03947385ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- University of Pennsylvania, Perelamn Center for Advanced Medicine, Philadelphia
- Thomas Jefferson University, Honickman Center, Philadelphia
- Fox Chase Cancer Center, Philadelphia
- dan 1 lainnya
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Mei 2026 · NCT03686124Neoadjuvant Darovasertib in Primary Uveal Melanoma
- Jefferson Health Honickman Center, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Mei 2026 · NCT07015190A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- Thomas Jefferson University, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
Menerima pesertaFase 2/3
Semua usia · Semua jenis kelamin · Diperbarui 2 Apr 2026 · NCT06581406Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.